Work

Calcitonin gene-related peptide inhibition: the advent of biologics in rosacea

Year: 2025

Type: article

Abstract: Persistent facial erythema and flushing in rosacea remain challenging to treat with current therapies. A recent noteworthy open-label trial found that erenumab, a calcitonin gene-related peptide receptor inhibitor, significantly reduced moderate to extreme flushing and erythema in patients with treatment-resistant disease, highlighting a novel neurovascular-targeted therapeutic approach.

Source: Clinical and Experimental Dermatology

DOI: 10.1093/ced/llaf299

Authors: Gurnoor Kaur, Ria Bhatt, Yan Ching Chow, Chawalpat Siripanich, Faisal R Ali

Institutions: University of Lancashire, Mid Cheshire Hospitals NHS Foundation Trust

Language: English

Topic: Acne and Rosacea Treatments and Effects

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,354